GeneReach Biotechnology Corp. (TPEX:4171)
Taiwan · Delayed Price · Currency is TWD 16.15
0.00 (0.00%)
Sep 15, 2026, 1:30 PM CST
GeneReach Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 918 | 1,085 | 1,646 | 2,267 | 3,034 | 3,794 | |
Market Cap Growth | -12.70% | -34.10% | -27.38% | -25.28% | -20.04% | -27.82% |
Enterprise Value | 848 | 1,059 | 1,453 | 2,018 | 2,509 | 3,642 |
Last Close Price | 16.15 | 18.80 | 28.65 | 39.45 | 51.29 | 60.29 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 13.71 | 10.07 |
Forward PE | - | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 |
PS Ratio | 3.86 | 4.66 | 7.97 | 10.05 | 4.05 | 3.75 |
PB Ratio | 1.58 | 1.82 | 2.27 | 2.63 | 2.75 | 3.49 |
P/TBV Ratio | 1.64 | 1.90 | 2.34 | 2.77 | 2.87 | 3.65 |
P/FCF Ratio | 726.47 | - | - | - | 9.86 | 11.52 |
P/OCF Ratio | 67.35 | - | - | - | 8.48 | 10.87 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.56 | 4.55 | 7.04 | 8.95 | 3.35 | 3.60 |
EV/EBITDA Ratio | 162.15 | - | - | - | 8.57 | 6.86 |
EV/EBIT Ratio | - | - | - | - | 10.40 | 7.55 |
EV/FCF Ratio | 670.53 | - | - | - | 8.15 | 11.06 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.37 | 0.37 | 0.37 | 0.29 | 0.35 | 0.34 |
Debt / EBITDA Ratio | 40.82 | - | - | - | 1.28 | 0.68 |
Debt / FCF Ratio | 168.78 | - | - | - | 1.27 | 1.12 |
Net Debt / Equity Ratio | -0.14 | -0.12 | -0.20 | -0.29 | -0.32 | -0.27 |
Net Debt / EBITDA Ratio | 12.31 | 3.18 | 2.10 | 1.46 | -1.23 | -0.55 |
Net Debt / FCF Ratio | -62.88 | 3.56 | 4.84 | 4.08 | -1.16 | -0.89 |
Asset Turnover | 0.26 | 0.24 | 0.18 | 0.16 | 0.45 | 0.69 |
Inventory Turnover | 1.61 | 2.05 | 1.68 | 1.31 | 1.03 | 1.05 |
Quick Ratio | 1.64 | 1.65 | 1.92 | 2.55 | 2.09 | 3.09 |
Current Ratio | 2.41 | 2.41 | 2.48 | 3.07 | 2.78 | 4.24 |
Return on Equity (ROE) | -7.60% | -17.08% | -15.58% | -17.34% | 19.86% | 38.08% |
Return on Assets (ROA) | -3.70% | -5.13% | -7.31% | -10.24% | 9.12% | 20.61% |
Return on Invested Capital (ROIC) | -10.47% | -14.46% | -22.11% | -33.91% | 25.05% | 49.89% |
Return on Capital Employed (ROCE) | -8.10% | -11.70% | -15.90% | -23.60% | 19.50% | 34.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -4.69% | -10.17% | -7.21% | -7.33% | 7.30% | 9.93% |
FCF Yield | 0.14% | -1.83% | -1.84% | -2.74% | 10.14% | 8.68% |
Dividend Yield | - | - | - | - | 2.34% | 6.03% |
Payout Ratio | - | - | - | - | 94.40% | 38.15% |
Buyback Yield / Dilution | 1.30% | 0.79% | - | 3.08% | -1.13% | -1.88% |
Total Shareholder Return | 1.30% | 0.79% | - | 3.08% | 1.21% | 4.15% |